- In May 2022, Intercept Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for treating patients suffering from primary biliary cholangitis (PBC) who have not achieved an adequate biochemical response to ursodeoxycholic acid
